Valdecoxib for the management of chronic and acute pain

References

• Parrott T. Pain management in primary- care medical practice. In: Practical Pain Management. Third Edition. Tollison CD, Satterthwaithe JR, Tollison JW (Eds). Lippincott Williams & Wilkins, PA, USA, 729–759 (2002).
   Google Scholar
• Bartel J, Beasley J, Berry PH. Approaches to pain management. Joint Commission on Accreditation of Healthcare Organizations, IL, USA (2003).
   Google Scholar
• Caudill MA, Holman GH, Turk DC. Effective ways to manage chronic pain. Patient Care30(11), 154–172 (1996).
   Google Scholar
• Bostrom M. Summary of the Mayday Fund Survey: public attitudes about pain and analgesics. J. Pain Symptom. Manage.13, 166–168 (1997).
   Web of Science ®Google Scholar
• Portenoy RK, Lesage P. Management of cancer pain. Lancet353, 1695–1700 (1999).
   PubMed Web of Science ®Google Scholar
• Levy MH. Pharmacologic treatment of cancer pain. N. Engl. J. Med.335, 1124–1132 (1996).
   PubMed Web of Science ®Google Scholar
• Cherny N. New strategies in opioid therapy for cancer pain. J. Oncol. Manag.9, 8–15 (2000).
   PubMedGoogle Scholar
• McQuay H. Opioids in pain management. Lancet353, 2229–2232 (1999).
   PubMed Web of Science ®Google Scholar
• Graham GG, Graham RI, Day RO. Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol). Curr. Pharm. Des.8, 1063–1075 (2002).
   PubMed Web of Science ®Google Scholar
• Botting RM. Mechanism of action of acetaminophen: is there a cyclooxygenase 3? Clin. Infect. Dis.31(Suppl. 5), S202–S210 (2000).
   Web of Science ®Google Scholar
• Towheed TE, Judd MJ, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. Cochrane. Database. Syst. Rev.CD004257 (2003).
   Google Scholar
• Wolfe F, Zhao S, Lane N. Preference for nonsteroidal anti-inflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum.43, 378–385 (2000).
   PubMed Web of Science ®Google Scholar
• Pincus T, Swearingen C, Cummins P, Callahan LF. Preference for nonsteroidal anti-inflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis. J. Rheumatol.27, 1020–1027 (2000).
   PubMed Web of Science ®Google Scholar
• Ostapowicz G, Fontana RJ, Schiodt FV et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med.137, 947–954 (2002).
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Hernandez-Diaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti inflammatory drugs. Epidemiology12, 570–576 (2001).
   PubMed Web of Science ®Google Scholar
• Rahme E, Pettitt D, LeLorier J. Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal anti-inflammatory drugs in an elderly population. Arthritis Rheum.46, 3046–3054 (2002).
   PubMed Web of Science ®Google Scholar
• Locke GR III, Zinsmeister AR, Talley NJ, Fett SL, Melton LJ. Risk factors for irritable bowel syndrome: role of analgesics and food sensitivities. Am. J. Gastroenterol.95, 157–165 (2000).
   PubMed Web of Science ®Google Scholar
• Laine L. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. Semin. Arthritis Rheum.32, 25–32 (2002).
   PubMed Web of Science ®Google Scholar
• Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N. Engl. J. Med.340, 1888–1899 (1999).
   PubMed Web of Science ®Google Scholar
• Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am. J. Med.105, S31–S38 (1998).
   PubMedGoogle Scholar
• Marret E, Flahault A, Samama CM, Bonnet F. Effects of postoperative, nonsteroidal, anti-inflammatory drugs on bleeding risk after tonsillectomy: meta-analysis of randomized, controlled trials. Anesthesiology98, 1497–1502 (2003).
   PubMed Web of Science ®Google Scholar
• Lawrence C, Sakuntabhai A, Tiling-Grosse S. Effect of aspirin and nonsteroidal anti- inflammatory drug therapy on bleeding complications in dermatologic surgical patients. J. Am. Acad. Dermatol.31, 988–992 (1994).
   Google Scholar
• Catella-Lawson F, Crofford LJ. Cyclooxygenase inhibition and thrombogenicity. Am. J. Med.110(Suppl. 3A), S28-S32 (2001).
   PubMedGoogle Scholar
• Bakhle YS, Botting RM. Cyclooxygenase-2 and its regulation in inflammation. Mediators Inflamm.5, 305–323 (1996).
   Google Scholar
• Seibert K, Zhang Y, Leahy K et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain. Proc. Natl Acad. Sci. USA91, 12013–12017 (1994).
   PubMed Web of Science ®Google Scholar
• Wang LH, Hajibeigi A, Xu XM, Loose- Mitchell D, Wu KK. Characterization of the promoter of human prostaglandin H synthase-1 gene. Biochem. Biophys. Res. Comm.190, 406–411 (1993).
   PubMed Web of Science ®Google Scholar
• O’Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett.330, 156–160 (1993).
   PubMed Web of Science ®Google Scholar
• Singh G, Mithal A, Triadafilopoulos G. Decreasing rates of hospitalizations due to complicated gastric and duodenal ulcers in the United States from 1988 to 2001. Ann. Rheum. Dis.63(Suppl. 1), 519 (2004).
   Google Scholar
• Singh G, Mithal A, Triadafilopoulos G. Age, hospitalizations, and case fatality rates due to complicated gastric and duodenal ulcers in the United States: how old is old? Ann. Rheum. Dis.63(Suppl. 1), 519 (2004).
   Google Scholar
• Jain KK. Evaluation of intravenous parecoxib for the relief of acute post- surgical pain. Expert Opin. Investig. Drugs9, 2717–2723 (2000).
   PubMed Web of Science ®Google Scholar
• Talley JJ, Brown DL, Carter JS et al. 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J. Med. Chem.43, 775–777 (2000).
   PubMed Web of Science ®Google Scholar
• Riendeau D, Percival MD, Brideau C et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J. Pharmacol. Exp. Ther.296, 558–566 (2001).
   PubMed Web of Science ®Google Scholar
• Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Natl Acad. Sci. USA96, 7563–7568 (1999).
   PubMed Web of Science ®Google Scholar
• Gierse JK, Zhang Y, Hood WF et al. Valdecoxib: assessment of COX-2 potency and selectivity. J. Pharmacol. Exp. Ther. (2004) (In Press).
   Google Scholar
• Leese PT, Talwalker S, Kent JD, Recker DP. Valdecoxib does not impair platelet function. Am. J. Emerg. Med.20, 275–281 (2002).
   PubMedGoogle Scholar
• Leese PT, Recker DP, Kent JD. The COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial.J. Clin. Pharmacol.43, 504–513 (2003).
   PubMed Web of Science ®Google Scholar
• Makarowski W, Zhao WW, Bevirt T, Recker DP. Efficacy and safety of the COX- 2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo- controlled comparison with naproxen. Osteoarthritis. Cartilage10, 290–296 (2002).
   PubMed Web of Science ®Google Scholar
• Kivitz A, Eisen G, Zhao WW, Bevirt T, Recker DP. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J. Fam. Pract.51, 530–537 (2002).
   PubMed Web of Science ®Google Scholar
• Fiechtner JJ, Sikes DH, Recker DP. A double-blind, placebo-controlled dose ranging study to evaluate the efficacy of valdecoxib, a novel COX-2 specific inhibitor, in treating the signs and symptoms of osteoarthritis of the knee. European Congress of Rheumatology, Prague, Czech Republic (2001).
   Google Scholar
• Moskowitz RW, Jones JB. Valdecoxib 10mg demonstrates a rapid onset of action following a single dose in patients with OA of the knee in a flare state. Ann. Rheum. Dis.62, 279 (2003).
   Google Scholar
• Bensen W, Weaver A, Espinoza L et al. Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen. Rheumatology41, 1008–1016 (2002).
   PubMed Web of Science ®Google Scholar
• Pavelka K, Recker DP, Verburg KM. Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial. Rheumatology42, 1207–1215 (2003).
   PubMed Web of Science ®Google Scholar
• Daniels SE, Talwalker S, Torri S, Snabes MC, Recker DP, Verburg KM. Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea. Obstet. Gynecol.100, 350–358 (2002).
   Web of Science ®Google Scholar
• Daniels SE, Torri S, Desjardins PJ. Valdecoxib for treatment of primary dysmenorrhea: a randomized, double-blind comparison with placebo and naproxen. J. Gen. Intern. Med. (2004) (In Press).
   Google Scholar
• Daniels SE, Torri S, Snabes MC. Efficacy of valdecoxib versus naproxen sodium in primary dysmenorrhea. Obstet. Gynecol.99, S30 (2002).
   Google Scholar
• Thomas H, Le V, Brown MT. Valdecoxib effectively treats a single moderate or severe acute migraine headache. Headache43, 523–524 (2003).
   Google Scholar
• Thomas HM, Kudrow MD, Ashford EA. A Phase III multicenter, randomized, double- blind, parallel-group study of valdecoxib 40 mg vs. placebo in patients with multiple moderate or severe acute migraine headaches with or without aura. Cephalgia23, 697 (2003).
   Google Scholar
• Daniels SE, Desjardins PJ, Talwalker S, Recker DP, Verburg KM. The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery. J. Am. Dent. Assoc.133, 611–621 (2002).
   PubMedGoogle Scholar
• Fricke J, Varkalis J, Zwillich S et al. Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery. Am. J. Ther.9, 89–97 (2002).
   PubMedGoogle Scholar
• Christensen KS, Cawkwell GD. Valdecoxib versus rofecoxib in acute postsurgical pain: results of a randomized controlled trial. J. Pain Symptom Manage.27, 460–470 (2004).
   PubMedGoogle Scholar
• Desjardins PJ, Shu VS, Recker DP, Verburg KM, Woolf CJ. A single preoperative oral dose of valdecoxib, a new cyclooxygenase-2 specific inhibitor, relieves post-oral surgery or bunionectomy pain. Anesthesiology97, 565–573 (2002).
   PubMed Web of Science ®Google Scholar
• Daniels S, Katz J, Bandy D, Jain R. Analgesic efficacy of valdecoxib in oral surgery pain: a comparison of preoperative and postoperative dosing. J. Pain4, 81 (2003).
   Google Scholar
• Reynolds LW, Hoo RK, Brill RJ, North J, Recker DP, Verburg KM. The COX-2 specific inhibitor, valdecoxib, is an effective, opioid-sparing analgesic in patients undergoing total knee arthroplasty. J. Pain Symptom. Manage25, 133–141 (2003).
   PubMedGoogle Scholar
• Camu F, Beecher T, Recker DP, Verburg KM. Valdecoxib, a COX-2-specific inhibitor, is an efficacious, opioid-sparing analgesic in patients undergoing hip arthroplasty. Am. J. Ther.9, 43–51 (2002).
   PubMedGoogle Scholar
• Joshi GP, Viscusi ER, Gan TJ et al. Effective treatment of laparoscopic cholecystectomy pain with intravenous followed by oral COX-2 specific inhibitor. Anesth. Analg.98, 336–342 (2004).
   Google Scholar
• Zhao SZ, Chung F, Hanna DB, Raymundo AL, Cheung RY, Chen C. Dose-response relationship between opioid use and adverse effects after ambulatory surgery. J. Pain Symptom. Manage28, 35–46 (2004).
   PubMed Web of Science ®Google Scholar
• Gan TJ, Joshi GP, Zhao SZ, Hanna DB, Cheung RY, Chen C. Presurgical intravenous parecoxib sodium and follow- up oral valdecoxib for pain management after laproscopic cholecystectomy surgery reduces opioid requirements and opioid- related adverse effects. Acta Anaesthesiol. Scand.48, 1194–204 (2004).
   PubMed Web of Science ®Google Scholar
• Eisen G, Agrawal N, Kent JD, Recker DP. Valdecoxib has a GI safety and tolerability profile superior to nonselective NSAIDs and similar to placebo in arthritis patients under 55 years. Arthritis Rheum.46, 158–159 (2002).
   Google Scholar
• Fenton C, Keating GM, Wagstaff AJ. Valdecoxib: a review of its use in the management of osteoarthritis, rheumatoid arthritis, dysmenorrhoea and acute pain. Drugs64, 1231–1261 (2004).
   PubMed Web of Science ®Google Scholar
• Sikes DH, Agrawal NM, Zhao WW, Kent JD, Recker DP, Verburg KM. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur. J. Gastroenterol. Hepatol.14, 1101–1111 (2002).
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Kivitz AJ, Verburg KM, Recker DP, Palmer RC, Kent JD. A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects. Aliment Pharmacol. Ther.18, 125–132 (2003).
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Kent J, Shu V, Maurath C, Recker D, Verburg K. Valdecoxib is less ulcerogenic than conventional NSAIDs in osteoarthritis (OA) and rheumatoid arthritis (RA) patients with high risk of peptic ulcer disease. Gastroenterology122, A344 (2002).
   Google Scholar
• Goldstein JL, Eisen GM, Agrawal N, Stenson WF, Kent JD, Verburg KM. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib. Aliment Pharmacol. Ther.20, 527–538 (2004).
   PubMed Web of Science ®Google Scholar
• Brater DC. Effects of nonsteroidal anti inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition. Am. J. Med.107, S65–S70 (1999).
   PubMedGoogle Scholar
• Whelton A, White WB, Kent JD, Verburg KM. Hypertension and edema rates in 6717 patients for the new COX-2 specific inhibitor, valdecoxib, versus conventional nonspecific NSAIDS and placebo. Proceedings presented at the American Society of Hematology, CA, USA (2003).
   Google Scholar
• Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med.343, 1520–1528 (2000).
   PubMed Web of Science ®Google Scholar
• White WB, Strand V, Roberts R, Whelton A. Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal anti-inflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. Am. J. Ther.11, 244–250 (2004).
   Google Scholar
• Ott E, Nussmeier NA, Duke PC et al. Efficacy and safety of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg.125, 1481–1492 (2003).
   PubMed Web of Science ®Google Scholar
• New warnings for Bextra. FDA. Consum.37, 5 (2003).
   Google Scholar
• Glasser DL, Burroughs SH. Valdecoxib- induced toxic epidermal necrolysis in a patient allergic to sulfa drugs. Pharmacotherapy23, 551–553 (2003).
   Google Scholar
• Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science288, 1765–1769 (2000).
   PubMed Web of Science ®Google Scholar
• Kissin I. Preemptive analgesia. Anesthesiology93, 1138–1143 (2000).
   PubMed Web of Science ®Google Scholar
• Samad TA, Sapirstein A, Woolf CJ. Prostanoids and pain: unraveling mechanisms and revealing therapeutic targets. Trends Mol. Med.8, 390–396 (2002).
   PubMed Web of Science ®Google Scholar
• Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum.43, 1905–1915 (2000).
   PubMed Web of Science ®Google Scholar
• Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum.46, 328–346 (2002).
   PubMed Web of Science ®Google Scholar
• AGS clinical practice guidelines: the management of chronic pain in older persons. Geriatrics.53(Suppl. 3), S6–S7 (1998).
   Google Scholar
• Jordan KM, Arden NK, Doherty M et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann. Rheum. Dis.62, 1145–1155 (2003).
   PubMed Web of Science ®Google Scholar
• Gajraj NM. The effect of cyclooxygenase-2 inhibitors on bone healing. Reg. Anesth. Pain Med.28, 456–465 (2003).
   PubMed Web of Science ®Google Scholar
• Alsalameh S, Burian M, Mahr G, Woodcock BG, Geisslinger G. Review article: the pharmacological properties and clinical use of valdecoxib, a new cyclo- oxygenase-2-selective inhibitor. Aliment Pharmacol. Ther.17, 489–501 (2003).
   PubMed Web of Science ®Google Scholar